AstraZeneca to sell asthma and rhinitis drug rights to Covis Pharma for $350m

This article was originally published here

The Switzerland-based Covis Pharma will also make conditional sales-related payments for the three over-the-counter (OTC) drugs of up to $21m over four years from 2019. AstraZeneca global product

The post AstraZeneca to sell asthma and rhinitis drug rights to Covis Pharma for $350m appeared first on Pharma Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply